

Analysis of Monkeypox Virus with RT-qPCR Validation Data

8. Verification and Validation procedures and results

8.1. Sample preparation for the MonkeyPox verification testing

1. Prepare Serial Dilutions according to the table Below.

Table 10. Serial dilution of BEI MonkeyPox virus DNA which was used as PC- QPCR for Assay Verification was carried.

Serial Dilution	Stock/Dilution Volume (uL)	NFW (uL)	Final Volume (uL)	Concentration copies/uL	Notes
1	9	26	35	1000	9uL of Working Stock
2	15	15	30	500	15uL of Dilution 1
3	15	15	30	250	15uL of Dilution 2
4	15	15	30	125	15uL of Dilution 3
5	15	15	30	62.5	15uL of Dilution 4
6	15	15	30	31.25	15uL of Dilution 5
7	15	15	30	15.625	15uL of Dilution 6

Results: LOD for the PC verification using BEI control DNA

Well Position	Sample	Target	Reporter	Amp Status	Cq	Cq Confidence
A1	1000-1	MPXV	FAM	Amp	28.45	0.89
A1	1000-1	RNaseP	VIC	Amp	27.21	0.99
A2	1000-2	MPXV	FAM	Amp	28.83	0.99
A2	1000-2	RNaseP	VIC	Amp	27.72	0.99
A3	1000-3	MPXV	FAM	Amp	28.71	0.99
A3	1000-3	RNaseP	VIC	Amp	27.61	0.99
B1	500-1	MPXV	FAM	Amp	29.52	0.95
B1	500-1	RNaseP	VIC	Amp	27.93	0.99
B2	500-2	MPXV	FAM	Amp	29.74	0.99
B2	500-2	RNaseP	VIC	Amp	28.37	0.99
B3	500-3	MPXV	FAM	Amp	29.71	0.99
B3	500-3	RNaseP	VIC	Amp	29.09	0.98
C1	250-1	MPXV	FAM	Amp	27.21	0.18
C1	250-1	RNaseP	VIC	Amp	27.21	0.66
C2	250-2	MPXV	FAM	Amp	29.88	0.63
C2	250-2	RNaseP	VIC	Amp	29.07	0.99
C3	250-3	MPXV	FAM	Amp	30.31	0.99
C3	250-3	RNaseP	VIC	Amp	29.47	0.99
D1	125-1	MPXV	FAM	Amp	31.88	0.99
D1	125-1	RNaseP	VIC	Amp	31.06	0.99
D2	125-2	MPXV	FAM	Amp	30.31	0.78
D2	125-2	RNaseP	VIC	Amp	30.60	0.99

MonkeyPox Assay Report

D3	125-3	MPXV	FAM	Amp	31.68	0.99
D3	125-3	RNaseP	VIC	Amp	31.19	0.99
E1	62.5-1	MPXV	FAM	Amp	31.24	0.93
E1	62.5-1	RNaseP	VIC	Amp	31.66	0.99
E2	62.5-2	MPXV	FAM	Amp	32.77	0.98
E2	62.5-2	RNaseP	VIC	Amp	31.37	0.99
E3	62.5-3	MPXV	FAM	No Amp	Undetermined	0.00
E3	62.5-3	RNaseP	VIC	No Amp	Undetermined	0.00
F1	31.25-1	MPXV	FAM	Amp	31.62	0.72
F1	31.25-1	RNaseP	VIC	Amp	32.51	0.98
F2	31.25-2	MPXV	FAM	Inconclusive	34.11	0.99
F2	31.25-2	RNaseP	VIC	Amp	33.82	0.99
F3	31.25-3	MPXV	FAM	Amp	33.86	0.98
F3	31.25-3	RNaseP	VIC	Amp	32.53	0.99
G1	15.625-1	MPXV	FAM	No Amp	Undetermined	0.00
G1	15.625-1	RNaseP	VIC	Amp	33.88	0.99
G2	15.625-2	MPXV	FAM	Inconclusive	35.14	0.97
G2	15.625-2	RNaseP	VIC	Amp	33.97	0.98
G3	15.625-3	MPXV	FAM	Inconclusive	35.01	0.97
G3	15.625-3	RNaseP	VIC	Amp	33.84	0.99
H1	NEC	MPXV	FAM	No Amp	Undetermined	0.00
H1	NEC	RNaseP	VIC	No Amp	Undetermined	0.00
H2	NEC2	MPXV	FAM	No Amp	Undetermined	0.00
H2	NEC2	RNaseP	VIC	No Amp	Undetermined	0.00
H10	NTC	MPXV	FAM	Inconclusive	36.35	0.00
H10	NTC	RNaseP	VIC	Amp	36.35	0.95
H11	NTC	MPXV	FAM	No Amp	Undetermined	0.00
H11	NTC	RNaseP	VIC	Amp	35.97	0.98
H12	NTC	MPXV	FAM	No Amp	Undetermined	0.00
H12	NTC	RNaseP	VIC	Amp	37.04	0.94

Patient 1 and 2 verification using the LA and NY county confirm sample

Samples were collected using the saliva spectrum and specimax saliva kit and run.

	Well Position	Sample	Target	Reporter	Amp Status	Cq	Cq Confidence
Patient 1 (Sal-Spectrum kit, MAX-Specimax kit)	A1	NEC	MPXV	FAM	No Amp	Undetermined	0.00
	A1	NEC	RNaseP	VIC	Inconclusive	37.70	0.95
	D1	SAL1	MPXV	FAM	Amp	31.08	0.96
	D1	SAL1	RNaseP	VIC	Amp	12.94	0.88
	D2	SAL2	MPXV	FAM	Amp	33.24	0.68
	D2	SAL2	RNaseP	VIC	Amp	13.33	0.86
	D3	SAL3	MPXV	FAM	Amp	31.61	0.97
	D3	SAL3	RNaseP	VIC	Amp	12.76	0.87
	D4	SAL4	MPXV	FAM	Amp	29.94	0.97
	D4	SAL4	RNaseP	VIC	Amp	11.98	0.89
	D5	SAL5	MPXV	FAM	Amp	30.40	0.98
	D5	SAL5	RNaseP	VIC	Amp	12.41	0.89
	D6	SAL6	MPXV	FAM	Amp	30.94	0.98
	D6	SAL6	RNaseP	VIC	Amp	12.37	0.86
	D7	SAL7	MPXV	FAM	Amp	32.83	0.85
	D7	SAL7	RNaseP	VIC	Amp	12.90	0.82
	D8	SAL8	MPXV	FAM	Amp	30.10	0.99
	D8	SAL8	RNaseP	VIC	Amp	13.16	0.87
D9	SAL9	MPXV	FAM	Amp	32.76	0.78	
D9	SAL9	RNaseP	VIC	Amp	13.36	0.57	

MonkeyPox Assay Report

	E1	MAX1	MPXV	FAM	Amp	31.87	0.99	
	E1	MAX1	RNaseP	VIC	Amp	17.96	0.87	
	E2	MAX2	MPXV	FAM	Amp	29.75	0.97	
	E2	MAX2	RNaseP	VIC	Amp	18.57	0.94	
	E3	MAX3	MPXV	FAM	Amp	31.23	0.99	
	E3	MAX3	RNaseP	VIC	Amp	13.24	0.84	
	E4	MAX4	MPXV	FAM	Amp	30.32	0.99	
	E4	MAX4	RNaseP	VIC	Amp	14.88	0.84	
	E5	MAX5	MPXV	FAM	Amp	31.60	0.98	
	E5	MAX5	RNaseP	VIC	Amp	15.15	0.85	
	E6	MAX6	MPXV	FAM	Amp	30.79	0.99	
	E6	MAX6	RNaseP	VIC	Amp	15.40	0.78	
	E7	MAX7	MPXV	FAM	Amp	31.81	0.97	
	E7	MAX7	RNaseP	VIC	Amp	15.94	0.83	
	E8	MAX8	MPXV	FAM	Amp	30.91	0.99	
	E8	MAX8	RNaseP	VIC	Amp	16.90	0.84	
	E9	MAX9	MPXV	FAM	Amp	34.34	0.87	
	E9	MAX9	RNaseP	VIC	Amp	19.84	0.89	
	P24	NTC	MPXV	FAM	Inconclusive	36.54	0.00	
	P24	NTC	RNaseP	VIC	Inconclusive	36.62	0.94	
Patient 2 (sal- spectrum saliva kit)	A13	NEC	MPXV	FAM	No Amp	Undetermined	0.00	
	A13	NEC	RNaseP	VIC	Inconclusive	39.23	0.00	
	A14	Sal1	MPXV	FAM	Amp	23.89	0.90	
	A14	Sal1	RNaseP	VIC	Amp	16.81	0.78	
	A15	Sal2	MPXV	FAM	Amp	25.44	0.98	
	A15	Sal2	RNaseP	VIC	Amp	16.42	0.83	
	A16	Sal3	MPXV	FAM	Amp	19.65	0.17	
	A16	Sal3	RNaseP	VIC	Amp	12.95	0.77	
	A17	Sal4	MPXV	FAM	Amp	23.50	0.98	
	A17	Sal4	RNaseP	VIC	Amp	17.15	0.80	
	A18	Sal5	MPXV	FAM	Amp	21.43	0.98	
	A18	Sal5	RNaseP	VIC	Amp	16.30	0.87	
	A19	Sal6	MPXV	FAM	Amp	15.11	0.04	
	A19	Sal6	RNaseP	VIC	Amp	12.99	0.63	
	A20	Sal7	MPXV	FAM	Amp	21.32	0.57	
	A20	Sal7	RNaseP	VIC	Amp	16.75	0.85	
	A21	Sal8	MPXV	FAM	Amp	22.28	0.89	
	A21	Sal8	RNaseP	VIC	Amp	17.17	0.89	
		E12	NTC-1	MPXV	FAM	No Amp	Undetermined	0.00
		E12	NTC-1	RNaseP	VIC	Amp	36.04	0.97
		F12	NTC-2	MPXV	FAM	Inconclusive	35.72	0.02
		F12	NTC-2	RNaseP	VIC	Inconclusive	37.08	0.96
		G12	NTC-3	MPXV	FAM	No Amp	Undetermined	0.00
		G12	NTC-3	RNaseP	VIC	Amp	35.00	0.97
		H12	PC	MPXV	FAM	Amp	26.24	0.70
		H12	PC	RNaseP	VIC	Amp	25.35	0.92

BEI control DNA will be used as PC for the studies.

8.2. Limit of Detection – Analytical Sensitivity

Limit of detection (LoD) studies was established by a 2-fold dilution series with pooled Negative saliva specimens' replicates with Thermo MonkeyPox virus DNA Control. To confirm the LoD, 20 replicates for the virus from the LoD determined in the preliminary range finding study were tested.

Acceptance criteria for the LoD study:

1. Preliminary LoD: The lowest concentration that gives MPXV positive results 100% of the time within the dilution series.
2. Final LoD: The lowest concentration at which $\geq 95\%$ of the replicates (i.e. 19/20 for virus) is positive.

Viral Single-use Stock		Working Stock Concentration (copies/uL)		Volume of Dilution Stock (uL)	Volume of NFW
Thermo Monkeypox virus DNA Control		1000		5	495
Serial Dilution	Stock/Dilution Volume (ul)	Negative saliva matrix(ul)		Final Volume (uL)	Concentration copies/ml
1	6	2996		1500	2000
2	1500	1500		1500	1000
3	1500	1500		1500	500
4	1500	1500		1500	250
5	1500	1500		1500	125
6	1500	1500		1500	62.5
7	1500	1500		1500	31

Results:

Table 12: Preliminary LoD

Preliminary LoD MonkeyPox(MPXV)							
Copies/mL	Replicates	MPXV Gene Ct	AMP Status	RNaseP ct	Amp Status	Interpretation	% Viral Positivity
MPXV-0	1	Undetermined	No Amp	16.17	Amp	Negative MPXV	0%
	2	Undetermined	No Amp	15.96	Amp	Negative MPXV	
	3	Undetermined	No Amp	15.97	Amp	Negative MPXV	
MPXV-31.25	1	Undetermined	No Amp	15.87	Amp	Negative MPXV	33%
	2	35.68	Amp	15.70	Amp	Positive MPXV	
	3	Undetermined	No Amp	15.84	Amp	Negative MPXV	
MPXV-62.5	1	34.07	Amp	15.46	Amp	Positive MPXV	66%
	2	34.11	Amp	15.62	Amp	Positive MPXV	
	3	Undetermined	No Amp	15.52	Amp	Negative MPXV	
MPXV-125	1	36.34	Amp	15.85	Amp	Positive MPXV	66%
	2	Undetermined	No Amp	15.76	Amp	Negative MPXV	
	3	34.78	Amp	15.78	Amp	Positive MPXV	
MPXV-250	1	34.58	Amp	15.76	Amp	Positive MPXV	100%
	2	34.60	Amp	15.80	Amp	Positive MPXV	
	3	35.71	Amp	15.62	Amp	Positive MPXV	
MPXV-500	1	34.72	Amp	15.84	Amp	Positive MPXV	100%
	2	32.64	Amp	15.89	Amp	Positive MPXV	
	3	34.13	Amp	15.82	Amp	Positive MPXV	
	1	33.00	Amp	15.65	Amp	Positive MPXV	100%

MPXV-1000	2	32.57	Amp	15.79	Amp	Positive MPXV	
	3	33.35	Amp	15.81	Amp	Positive MPXV	
MPXV-2000	1	31.91	Amp	15.89	Amp	Positive MPXV	100%
	2	31.92	Amp	15.73	Amp	Positive MPXV	
	3	31.54	Amp	15.59	Amp	Positive MPXV	
PC-1	1	17.75	Amp	17.48	Amp	Positive MPXV	100%
PC-2	2	28.69	Amp	26.54	Amp	Positive MPXV	100%
PC-3	3	17.47	Amp	17.32	Amp	Positive MPXV	100%
NTC-1	1	Undetermined	No Amp		No Amp	Negative MPXV	0%
NTC-2	2	Undetermined	No Amp		No Amp	Negative MPXV	0%
NTC-3	3	Undetermined	No Amp	Undetermined	No Amp	Negative MPXV	0%
NEC-1	1	Undetermined	No Amp	Undetermined	No Amp	Negative MPXV	0%
NEC-2	2	39.44	No Amp	Undetermined	No Amp	Negative MPXV	0%
NEC-3	3	Undetermined	No Amp	Undetermined	No Amp	Negative MPXV	0%

PC-Positive control, NTC-Non template control , NEC - Negative extraction control

Confirmation was run at 500 and 250 copies/ml to confirm the LOD of the assay.

Table 13. Confirmatory LoD

Serial Dilution	Stock/Dilution Volume(uL)	Saliva Negative matrix(uL)	Final Volume (uL)	Concentration copies/mL	Notes
1	9	17991	9000	500	90uL of working stock
2	9000	9000	18000	250	9000uL of Dilution 1

Table 14: Confirmatory LoD

MPXV Confirmation LoD							
Copies/mL	Replicates	MPXV Gene Ct	AMP Status	RNaseP ct	Amp Status	Interpretation	% Viral Positivity
250 cp/mL	1	32.10	Amp	16.98	Amp	MPXV Positive	100%
	2	31.61	Amp	16.90	Amp	MPXV Positive	
	3	33.69	Amp	16.75	Amp	MPXV Positive	
	4	33.05	Amp	17.05	Amp	MPXV Positive	
	5	31.33	Amp	16.86	Amp	MPXV Positive	
	6	31.94	Amp	16.87	Amp	MPXV Positive	
	7	31.65	Amp	16.79	Amp	MPXV Positive	
	8	31.34	Amp	16.96	Amp	MPXV Positive	
	9	32.29	Amp	16.96	Amp	MPXV Positive	
	10	32.27	Amp	16.98	Amp	MPXV Positive	
	11	32.18	Amp	17.10	Amp	MPXV Positive	
	12	32.39	Amp	16.91	Amp	MPXV Positive	
	13	30.91	Amp	16.90	Amp	MPXV Positive	
	14	31.56	Amp	16.92	Amp	MPXV Positive	
	15	32.47	Amp	16.87	Amp	MPXV Positive	

	16	32.29	Amp	16.91	Amp	MPXV Positive	
	17	32.50	Amp	16.96	Amp	MPXV Positive	
	18	31.52	Amp	16.98	Amp	MPXV Positive	
	19	33.51	Amp	17.02	Amp	MPXV Positive	
	20	32.83	Amp	17.09	Amp	MPXV Positive	
500 cp/mL	1	30.30	Amp	16.98	Amp	MPXV Positive	100%
	2	31.65	Amp	17.17	Amp	MPXV Positive	
	3	30.91	Amp	16.99	Amp	MPXV Positive	
	4	30.96	Amp	16.99	Amp	MPXV Positive	
	5	32.35	Amp	17.34	Amp	MPXV Positive	
	6	32.09	Amp	17.08	Amp	MPXV Positive	
	7	31.25	Amp	17.19	Amp	MPXV Positive	
	8	30.57	Amp	16.97	Amp	MPXV Positive	
	9	31.14	Amp	16.91	Amp	MPXV Positive	
	10	31.42	Amp	16.86	Amp	MPXV Positive	
	11	31.38	Amp	16.95	Amp	MPXV Positive	
	12	31.17	Amp	16.91	Amp	MPXV Positive	
	13	30.83	Amp	16.94	Amp	MPXV Positive	
	14	30.84	Amp	16.91	Amp	MPXV Positive	
	15	31.73	Amp	16.90	Amp	MPXV Positive	
	16	31.19	Amp	17.04	Amp	MPXV Positive	
	17	31.37	Amp	17.19	Amp	MPXV Positive	
	18	31.10	Amp	16.89	Amp	MPXV Positive	
	19	31.86	Amp	17.33	Amp	MPXV Positive	
	20	31.49	Amp	16.98	Amp	MPXV Positive	

Controls	MPXV Gene Ct	AMP Status	RNaseP ct	Amp Status	Interpretation
Positive Control	28.45	Amp	27.48	Amp	Pass
NEC	Undetermined	Undetermined	37.19	Amp	Pass
NTC	Undetermined	Undetermined	36.55	Amp	Pass

* Undetermined=UND=Not detected

MPXV Gene Ct average	MPXV Ct STDEV	RNaseP Gene ct Average	RNaseP Ct STDEV
32.17	0.73	16.94	0.09

Conclusion: A detection rate of 100% was achieved (n=20) at a concentration of 250 copies/ml.

8.3 Precision

Precision is defined as closeness of agreement between independent test results obtained under stipulated conditions. Precision is commonly determined by assessing repeatability (i.e., closeness of agreement between independent test results for the same measurement under the same conditions) and reproducibility (i.e., closeness of agreement between independent test results for the same measurement under changed conditions). Precision can be verified or established by assessing day-to-day, run-to-run, and within-run variation (as well as lot variance) by repeat testing of samples, quality control materials, or calibration materials over time.

Samples consisted of a pool of clinical saliva specimens in collection device which were negative for Monkeypox, with or without a purified viral spike-in to create defined viral concentrations.

At least two different operators and instruments were used on 3 separate days at 3 different concentrations (0.1x LoD, 2x LoD, and 5x LoD) of contrived specimens and one negative specimen in triplicate.

Acceptance criteria for precision:

1. 100% agreement for 2x LoD and 5x LoD, for virus.
2. Results at 0.1x LoD were reported (While all are likely to be negative, some may be positive due to stochastic factors in early PCR cycles or sample heterogeneity).

Table 15: Precision

Sample	LoD	Replicates	Precision Day 1					Precision Day 2					Precision Day 3				
			MPXV Gene Ct	AMP Status	RNa seP ct	Amp Status	Interpretation	MPXV Gene Ct	AMP Status	RNa seP ct	Amp Status	Interpretation	MPXV Gene Ct	AMP Status	RNa seP ct	Amp Status	Interpretation
MP XV	5x	1	30.69	Amp	16.02	Amp	MPXV Positive	33.13	Amp	16.33	Amp	MPXV Positive	31.25	Amp	15.79	Amp	MPXV Positive
MP XV	5x	2	30.87	Amp	16.01	Amp	MPXV Positive	32.52	Amp	16.21	Amp	MPXV Positive	32.21	Amp	16.00	Amp	MPXV Positive
MP XV	5x	3	27.65	Amp	15.16	Amp	MPXV Positive	32.82	Amp	16.07	Amp	MPXV Positive	33.40	Amp	15.72	Amp	MPXV Positive
MP XV	2x	1	33.15	Amp	15.63	Amp	MPXV Positive	34.78	Amp	16.54	Amp	MPXV Positive	34.53	Amp	15.95	Amp	MPXV Positive
MP XV	2x	2	31.41	Amp	15.51	Amp	MPXV Positive	35.93	Amp	16.20	Amp	MPXV Positive	34.43	Amp	15.99	Amp	MPXV Positive
MP XV	2x	3	33.25	Amp	15.54	Amp	MPXV Positive	34.19	Amp	16.19	Amp	MPXV Positive	32.82	Amp	15.75	Amp	MPXV Positive
MP XV	0.1x	1	UN D	No Amp	15.67	Amp	MPXV Negative	34.35	Amp	15.97	Amp	MPXV Positive	UN D	No Amp	15.84	Amp	MPXV Negative
MP XV	0.1x	2	UN D	No Amp	15.52	Amp	MPXV Negative	UN D	No Amp	16.20	Amp	MPXV Negative	36.33	Amp	15.67	Amp	MPXV Positive
MP XV	0.1x	3	UN D	No Amp	15.62	Amp	MPXV Negative	36.00	Amp	15.93	Amp	MPXV Positive	36.32	Amp	15.80	Amp	MPXV Positive
Neg -0-1	N/A	1	38.15	Inconclusive	15.42	Amp	MPXV Negative	UN D	No Amp	16.03	Amp	MPXV Negative	UN D	No Amp	15.88	Amp	MPXV Negative
Neg -0-2	N/A	2	UN D	No Amp	15.65	Amp	MPXV Negative	UN D	No Amp	16.22	Amp	MPXV Negative	UN D	No Amp	15.81	Amp	MPXV Negative
Neg -0-3	N/A	3	UN D	No Amp	15.83	Amp	MPXV Negative	UN D	No Amp	16.00	Amp	MPXV Negative	UN D	No Amp	15.72	Amp	MPXV Negative
PC	N/A	1	28.27	Amp	26.49	Amp	MPXV Positive	28.84	Amp	26.78	Amp	MPXV Positive	27.84	Amp	26.30	Amp	MPXV Positive
NE C	N/A	1	UN D	No Amp	35.35	Amp	MPXV Negative	UN D	No Amp	37.30	Inconclusive	MPXV Negative	UN D	No Amp	34.56	Amp	MPXV Negative
NE C-2	N/A	1	UN D	No Amp	34.89	Amp	MPXV Negative	UN D	No Amp	UN D	No Amp	MPXV Negative	UN D	No Amp	35.64	Amp	MPXV Negative
NT C	N/A	1	UN D	No Amp	36.58	Amp	MPXV Negative	UN D	No Amp	37.06	Inconclusive	MPXV Negative	UN D	No Amp	35.84	Amp	MPXV Negative

* Undetermined=UND=Not detected

	Average CT		SD		%CV	
	MPXV Gene Ct	RNaseP ct	MPXV Gene SD	RNaseP SD	MPXV Gene	RNaseP
5X	31.7	16.0	1.3	0.3	4.0	1.7
	31.9	16.1	0.9	0.1	2.7	0.7
	31.3	15.6	3.2	0.5	10.1	2.9
2X	34.2	16.0	0.9	0.5	2.6	2.9
	33.9	15.9	2.3	0.4	6.8	2.2
	33.4	15.8	0.7	0.3	2.1	2.1

Conclusion

Overall precision of the Monkeypox virus detection showed an acceptable Ct for all controls over a period of 3 days. Comparing across separate PCR plates on 3 days (inter-run) and within single PCR plates (intra-run), we showed 100% agreement between samples at 5X and 2x LoD and %CV of <20%.

The test performance agreement between the operators and instruments were > 95%. All negative controls were negative.

8.4 Accuracy/Clinical Evaluation

Accuracy is defined as the closeness of agreement between a test result and an accepted reference value. Analytical accuracy was determined by concordance between test results from LA and NY county. Two samples that were confirmed as positive for Monkeypox by the LA and NY county Health Departments were used for this study, in addition to 20 negative retrospectives saliva specimens (n=20). The positive samples were diluted into various concentrations in negative matrix.

This study will be a continued evaluation as we collect more specimens and confirm with other validated laboratories in the future.

The results from these studies are summarized in Table.

Table 16. Accuracy of assay

		Sample	Target	Reporter	Amp Status	Cq
Patient 1- Positive - Confirmed by Los Angeles county -Serial dilution in Negative saliva matrix- Making Contrived Positive samples.	B1	P1_Stock-1	MPXV	FAM	Amp	28.92
	B1	P1_Stock-1	RNaseP	VIC	Amp	13.25
	B2	P1_Stock-2	MPXV	FAM	Amp	27.52
	B2	P1_Stock-2	RNaseP	VIC	Amp	13.08
	B3	P1_Stock-3	MPXV	FAM	Amp	24.44
	B3	P1_Stock-3	RNaseP	VIC	Amp	13.11
	C1	P1-D1-1	MPXV	FAM	Amp	28.95
	C1	P1-D1-1	RNaseP	VIC	Amp	12.96
	C2	P1-D1-2	MPXV	FAM	Amp	30.30
	C2	P1-D1-2	RNaseP	VIC	Amp	13.00
	C3	P1-D1-3	MPXV	FAM	Amp	28.83
	C3	P1-D1-3	RNaseP	VIC	Amp	12.95
	D1	P1-D2-1	MPXV	FAM	Amp	30.81
	D1	P1-D2-1	RNaseP	VIC	Amp	13.70
	D2	P1-D2-2	MPXV	FAM	Amp	29.76
	D2	P1-D2-2	RNaseP	VIC	Amp	13.49
	D3	P1-D2-3	MPXV	FAM	Amp	31.49
	D3	P1-D2-3	RNaseP	VIC	Amp	13.69

MonkeyPox Assay Report

E1	P1-D3-1	MPXV	FAM	Amp	31.07	
E1	P1-D3-1	RNaseP	VIC	Amp	14.19	
E2	P1-D3-2	MPXV	FAM	Amp	31.55	
E2	P1-D3-2	RNaseP	VIC	Amp	14.21	
E3	P1-D3-3	MPXV	FAM	Amp	31.74	
E3	P1-D3-3	RNaseP	VIC	Amp	14.17	
F1	P1-D4-1	MPXV	FAM	Amp	29.57	
F1	P1-D4-1	RNaseP	VIC	Amp	14.21	
F2	P1-D4-2	MPXV	FAM	Amp	32.55	
F2	P1-D4-2	RNaseP	VIC	Amp	14.42	
F3	P1-D4-3	MPXV	FAM	Amp	32.61	
F3	P1-D4-3	RNaseP	VIC	Amp	14.43	
G1	P1-D5-1	MPXV	FAM	Amp	34.55	
G1	P1-D5-1	RNaseP	VIC	Amp	14.58	
G2	P1-D5-2	MPXV	FAM	No Amp	UND	
G2	P1-D5-2	RNaseP	VIC	Amp	14.70	
G3	P1-D5-3	MPXV	FAM	Amp	34.07	
G3	P1-D5-3	RNaseP	VIC	Amp	14.44	
H1	P1-D6-1	MPXV	FAM	No Amp	UND	
H1	P1-D6-1	RNaseP	VIC	Amp	14.73	
H2	P1-D6-2	MPXV	FAM	No Amp	UND	
H2	P1-D6-2	RNaseP	VIC	Amp	14.72	
H3	P1-D6-3	MPXV	FAM	No Amp	UND	
H3	P1-D6-3	RNaseP	VIC	Amp	14.65	
A4	NEG1	MPXV	FAM	No Amp	UND	
A4	NEG1	RNaseP	VIC	Amp	15.17	
A5	NEG2	MPXV	FAM	No Amp	UND	
A5	NEG2	RNaseP	VIC	Amp	14.79	
A6	NEG3	MPXV	FAM	No Amp	UND	
A6	NEG3	RNaseP	VIC	Amp	14.67	
H12	PC	MPXV	FAM	Amp	26.52	
H12	PC	RNaseP	VIC	Amp	25.03	
A1	NEC1	MPXV	FAM	No Amp	UND	
A1	NEC1	RNaseP	VIC	Amp	34.97	
A2	NEC2	MPXV	FAM	No Amp	UND	
A2	NEC2	RNaseP	VIC	No Amp	UND	
A3	NEC3	MPXV	FAM	No Amp	UND	
A3	NEC3	RNaseP	VIC	Amp	35.22	
P22	NTC1	MPXV	FAM	No Amp	UND	
P22	NTC1	RNaseP	VIC	No Amp	UND	
P23	NTC2	MPXV	FAM	Inconclusive	39.46	
P23	NTC2	RNaseP	VIC	No Amp	UND	
P24	NTC3	MPXV	FAM	Inconclusive	35.47	
P24	NTC3	RNaseP	VIC	No Amp	UND	
Patient2- Positive - Confirmed by New York county -Serial dilution in Negative saliva matrix- Making Contrived	A13	P2-Stock-1	MPXV	FAM	Amp	19.90
	A13	P2-Stock-1	RNaseP	VIC	Amp	15.54
	A14	P2-Stock-2	MPXV	FAM	Amp	24.43
	A14	P2-Stock-2	RNaseP	VIC	Amp	15.51
	A15	P2-Stock-3	MPXV	FAM	Amp	24.77
	A15	P2-Stock-3	RNaseP	VIC	Amp	15.74
	B13	P2-D1-1	MPXV	FAM	Amp	24.56
	B13	P2-D1-1	RNaseP	VIC	Amp	14.81
B14	P2-D1-2	MPXV	FAM	Amp	24.85	
B14	P2-D1-2	RNaseP	VIC	Amp	15.05	

MonkeyPox Assay Report

Positive samples.

B15	P2-D1-3	MPXV	FAM	Amp	24.84
B15	P2-D1-3	RNaseP	VIC	Amp	14.84
C13	P2-D2-1	MPXV	FAM	Amp	25.50
C13	P2-D2-1	RNaseP	VIC	Amp	14.86
C14	P2-D2-2	MPXV	FAM	Amp	26.06
C14	P2-D2-2	RNaseP	VIC	Amp	14.87
C15	P2-D2-3	MPXV	FAM	Amp	25.79
C15	P2-D2-3	RNaseP	VIC	Amp	14.79
D13	P2-D3-1	MPXV	FAM	Amp	26.53
D13	P2-D3-1	RNaseP	VIC	Amp	14.75
D14	P2-D3-2	MPXV	FAM	Amp	26.35
D14	P2-D3-2	RNaseP	VIC	Amp	14.70
D15	P2-D3-3	MPXV	FAM	Amp	26.76
D15	P2-D3-3	RNaseP	VIC	Amp	14.81
E13	P2-D4-1	MPXV	FAM	Amp	27.55
E13	P2-D4-1	RNaseP	VIC	Amp	14.96
E14	P2-D4-2	MPXV	FAM	Amp	27.69
E14	P2-D4-2	RNaseP	VIC	Amp	14.54
E15	P2-D4-3	MPXV	FAM	Amp	27.81
E15	P2-D4-3	RNaseP	VIC	Amp	14.70
F13	P2-D5-1	MPXV	FAM	Amp	28.98
F13	P2-D5-1	RNaseP	VIC	Amp	14.97
F14	P2-D5-2	MPXV	FAM	Amp	28.90
F14	P2-D5-2	RNaseP	VIC	Amp	14.92
F15	P2-D5-3	MPXV	FAM	Amp	28.66
F15	P2-D5-3	RNaseP	VIC	Amp	14.89
A16	P2-D6-1	MPXV	FAM	Amp	29.59
A16	P2-D6-1	RNaseP	VIC	Amp	14.85
A17	P2-D6-2	MPXV	FAM	Amp	29.30
A17	P2-D6-2	RNaseP	VIC	Amp	14.85
A18	P2-D6-3	MPXV	FAM	Amp	29.07
A18	P2-D6-3	RNaseP	VIC	Amp	14.98
B16	P2-D7-1	MPXV	FAM	Amp	30.06
B16	P2-D7-1	RNaseP	VIC	Amp	14.74
B17	P2-D7-2	MPXV	FAM	Amp	29.47
B17	P2-D7-2	RNaseP	VIC	Amp	14.64
B18	P2-D7-3	MPXV	FAM	Amp	29.97
B18	P2-D7-3	RNaseP	VIC	Amp	14.58
C16	P2-D8-1	MPXV	FAM	Amp	20.93
C16	P2-D8-1	RNaseP	VIC	Amp	13.69
C17	P2-D8-2	MPXV	FAM	Amp	19.18
C17	P2-D8-2	RNaseP	VIC	Amp	14.35
C18	P2-D8-3	MPXV	FAM	Amp	20.50
C18	P2-D8-3	RNaseP	VIC	Amp	13.81
D16	P2-D9-1	MPXV	FAM	Amp	24.60
D16	P2-D9-1	RNaseP	VIC	Amp	13.37
D17	P2-D9-2	MPXV	FAM	Amp	18.97
D17	P2-D9-2	RNaseP	VIC	Amp	13.36
D18	P2-D9-3	MPXV	FAM	Amp	18.35
D18	P2-D9-3	RNaseP	VIC	Amp	13.57
E16	P2-D10-1	MPXV	FAM	Amp	21.59
E16	P2-D10-1	RNaseP	VIC	Amp	13.26
E17	P2-D10-2	MPXV	FAM	Amp	19.90
E17	P2-D10-2	RNaseP	VIC	Amp	13.38

MonkeyPox Assay Report

E18	P2-D10-3	MPXV	FAM	Inconclusive	18.98
E18	P2-D10-3	RNaseP	VIC	Amp	13.49
F16	Neg-2-1	MPXV	FAM	Inconclusive	19.38
F16	Neg-2-1	RNaseP	VIC	Amp	13.43
F17	Neg-2-2	MPXV	FAM	Inconclusive	21.34
F17	Neg-2-2	RNaseP	VIC	Amp	13.49
F18	Neg-2-3	MPXV	FAM	No Amp	UND
F18	Neg-2-3	RNaseP	VIC	Amp	13.97
H12	PC	MPXV	FAM	Amp	27.46
H12	PC	RNaseP	VIC	Amp	25.84
A22	NEC-1	MPXV	FAM	No Amp	UND
A22	NEC-1	RNaseP	VIC	Inconclusive	37.69
A23	NEC-2	MPXV	FAM	No Amp	UND
A23	NEC-2	RNaseP	VIC	Amp	35.99
A24	NEC-3	MPXV	FAM	No Amp	UND
A24	NEC-3	RNaseP	VIC	Inconclusive	36.98
P22	NTC	MPXV	FAM	No Amp	UND
P22	NTC	RNaseP	VIC	Amp	37.44
P23	NTC	MPXV	FAM	No Amp	UND
P23	NTC	RNaseP	VIC	Inconclusive	38.15
P24	NTC	MPXV	FAM	No Amp	UND
P24	NTC	RNaseP	VIC	No Amp	UND

* Undetermined=UND=Not detected

Conclusion

All positive samples showed 100% concordance at different dilutions (Patient1- 6*3=24 and Patient 2- 9*3= 27). Ct values for RNaseP were < 33 for all samples indicating good extraction.

100% of the negative saliva samples showed negative results for Monkeypox virus.

Sample	Target	Amp Status	Cq
NEC	MPXV	No Amp	Undetermined
NEC	RNase P	Amp	37.94
POS-1	MPXV	No Amp	Undetermined
POS-1	RNase P	Amp	19.65
POS-2	MPXV	No Amp	Undetermined
POS-2	RNase P	Amp	15.64
POS-3	MPXV	No Amp	Undetermined
POS-3	RNase P	Amp	19.52
POS-4	MPXV	No Amp	Undetermined
POS-4	RNase P	Amp	14.59
POS-5	MPXV	No Amp	Undetermined
POS-5	RNase P	Amp	15.85
POS-6	MPXV	No Amp	Undetermined
POS-6	RNase P	Amp	19.92
POS-7	MPXV	No Amp	Undetermined
POS-7	RNase P	Amp	15.56
POS-8	MPXV	No Amp	Undetermined
POS-8	RNase P	Amp	16.90

POS-9	MPXV	No Amp	Undetermined
POS-9	RNase P	Amp	15.04
POS-10	MPXV	No Amp	Undetermined
POS-10	RNase P	Amp	17.79
POS-11	MPXV	No Amp	Undetermined
POS-11	RNase P	Amp	17.42
POS-12	MPXV	No Amp	Undetermined
POS-12	RNase P	Amp	17.79
POS-13	MPXV	No Amp	Undetermined
POS-13	RNase P	Amp	23.11
POS-14	MPXV	No Amp	Undetermined
POS-14	RNase P	Amp	15.73
POS-15	MPXV	No Amp	Undetermined
POS-15	RNase P	Amp	19.53
POS-16	MPXV	No Amp	Undetermined
POS-16	RNase P	Amp	22.83
POS-17	MPXV	No Amp	Undetermined
POS-17	RNase P	Amp	16.41
POS-18	MPXV	No Amp	Undetermined
POS-18	RNase P	Amp	20.39
POS-19	MPXV	No Amp	Undetermined
POS-19	RNase P	Amp	15.64
POS-20	MPXV	No Amp	Undetermined
POS-20	RNase P	Amp	18.13
PC	MPXV	Amp	27.74
PC	RNase P	Amp	26.87
NTC	MPXV	No Amp	Undetermined
NTC	RNase P	No Amp	Undetermined

8.5. Inclusivity (analytical reactivity)

ThermoFisher developed the primers and probe, documented the methodology and presented results of an in silico inclusivity analysis that established the extent to which variation in the Monkeypox genome may impact sensitivity of test performance. ThermoFisher TaqMan assay can detect both the clades of Monkeypox.

Thermo analysis is based on NCBI complete genomes.

Below is listed the isolates from 2022. All of them are detected by the assay.

	The list of previous strains matching the assay including Congo basin and West Africa
>ON631963.1 Monkeypox virus isolate MPxV/VIDRL01/2022, complete genome	AF380138.1_Monkeypox_virus_strain_Zaire-96-I-16
>ON637938.1 Monkeypox virus isolate MPXV/Germany/2022/RKI01, complete genome	AY603973.1_Monkeypox_virus_strain_MPXV-WRAIR7-61
>ON637939.1 Monkeypox virus isolate MPXV/Germany/2022/RKI02, complete genome	AY741551.1_Monkeypox_virus_isolate_Sierra_Leone
>ON631241.1 Monkeypox virus isolate 2022/2 SLO, complete genome	AY753185.1_Monkeypox_virus_strain_COP-58

MonkeyPox Assay Report

>ON627808.1 Monkeypox virus isolate MPX/human/USA/UT-UPHL-82200022/2022, complete genome	DQ011153.1_Monkeypox_virus_strain_USA_2003_044
>ON619835.1 Monkeypox virus isolate MPXV_UK_2022_1, complete genome	DQ011154.1_Monkeypox_virus_strain_Congo_2003_358
>ON619836.1 Monkeypox virus isolate MPXV_UK_2022_2, complete genome	DQ011155.1_Monkeypox_virus_strain_Zaire_1979-005
>ON619837.1 Monkeypox virus isolate MPXV_UK_2022_3, complete genome	DQ011156.1_Monkeypox_virus_strain_Liberia_1970_184
>ON619838.1 Monkeypox virus isolate MPXV_UK_2022_4, complete genome	DQ011157.1_Monkeypox_virus_strain_USA_2003_039
>ON622712.1 Monkeypox virus isolate MPX/UZ_REGA_1/Belgium/2022, complete genome	HM172544.1_Monkeypox_virus_strain_Zaire_1979-005
>ON622713.1 Monkeypox virus isolate MPX/UZ_REGA_2/Belgium/2022, complete genome	HQ857562.1_Monkeypox_virus_strain_V79-I-005
>ON622718.1 Monkeypox virus isolate MPXV/ES0001/HUGTIP/2022, partial genome	HQ857563.1_Monkeypox_virus_strain_D14L_knockout
>ON622720.1 Monkeypox virus isolate MPXV-CH-38156923/2022, partial genome	JX878407.1_Monkeypox_virus_isolate_DRC_06-0950
>ON622721.1 Monkeypox virus isolate MPXV_1_IT_Milan_2022, partial genome	JX878408.1_Monkeypox_virus_isolate_DRC_06-0970
>ON622722.1 Monkeypox virus isolate MPXV_FR_HCL0001_2022, complete genome	JX878417.1_Monkeypox_virus_isolate_DRC_07-0104
>ON609725.2 Monkeypox virus isolate SLO, complete genome	JX878418.1_Monkeypox_virus_isolate_DRC_07-0120
>ON614676.1 Monkeypox virus isolate INMI-Pt1, partial genome	JX878419.1_Monkeypox_virus_isolate_DRC_07-0275
>ON615424.1 Monkeypox virus isolate MPXV_2022_NL001, partial genome	JX878420.1_Monkeypox_virus_isolate_DRC_07-0283
>ON602722.1 Monkeypox virus isolate MPXV_FRA_2022_TLS67, complete genome	JX878423.1_Monkeypox_virus_isolate_DRC_07-0337
>ON585029.1 Monkeypox virus isolate Monkeypox/PT0001/2022, partial genome	JX878424.1_Monkeypox_virus_isolate_DRC_07-0338
>ON585030.1 Monkeypox virus isolate Monkeypox/PT0002/2022, partial genome	JX878425.1_Monkeypox_virus_isolate_DRC_07-0354
>ON585031.1 Monkeypox virus isolate Monkeypox/PT0003/2022, complete genome	JX878426.1_Monkeypox_virus_isolate_DRC_07-0450
>ON585032.1 Monkeypox virus isolate Monkeypox/PT0004/2022, complete genome	JX878429.1_Monkeypox_virus_isolate_DRC_07-0662
>ON585033.1 Monkeypox virus isolate Monkeypox/PT0006/2022, complete genome	KC257459.1_Monkeypox_virus_strain_Sudan_2005_01
>ON585034.1 Monkeypox virus isolate Monkeypox/PT0007/2022, complete genome	KC257460.1_Monkeypox_virus_strain_DRC_Yandongi_1985
>ON585035.1 Monkeypox virus isolate Monkeypox/PT0009/2022, complete genome	KJ642612.1_Monkeypox_virus_strain_Ikubi
>ON585036.1 Monkeypox virus isolate Monkeypox/PT0010/2022, partial genome	KJ642613.1_Monkeypox_virus_strain_Congo_8
>ON585037.1 Monkeypox virus isolate Monkeypox/PT0005/2022, complete genome	KJ642614.1_Monkeypox_virus_strain.UTC
>ON585038.1 Monkeypox virus isolate Monkeypox/PT0008/2022, complete genome	KJ642615.1_Monkeypox_virus_strain_W-Nigeria
>ON595760.2 Monkeypox virus isolate MPXV-CH-38134631/2022, partial genome	KJ642616.1_Monkeypox_virus_strain_PCH
>ON568298.1 Monkeypox virus isolate MPXV-BY-IMB25241, complete genome	KJ642617.1_Monkeypox_virus_strain_Nigeria-SE-1971
>ON563414.3 Monkeypox virus isolate MPXV_USA_2022_MA001, complete genome	KJ642618.1_Monkeypox_virus_strain_Cameroon-1990

MK783028.1_UNVERIFIED:_Monkeypox_virus_strain_3019	KJ642619.1_Monkeypox_virus_strain_Gabon-1988
MK783029.1_UNVERIFIED:_Monkeypox_virus_strain_3029	KP849469.1_Monkeypox_virus_isolate_Boende_DRC_2008
MK783030.1_UNVERIFIED:_Monkeypox_virus_strain_3025	KP849470.1_Monkeypox_virus_isolate_Cote_d'Ivoire_1971
MK783031.1_UNVERIFIED:_Monkeypox_virus_strain_3020	KP849471.1_Monkeypox_virus_isolate_Yambuku_DRC_1985
MK783032.1_UNVERIFIED:_Monkeypox_virus_strain_3030	MN648051.1_Monkeypox_virus_strain_Israel_2018
MN346690.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Bic	MT903337.1_Monkeypox_virus_isolate_MPXV-M2940_FCT
MN346692.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Mama	MT903338.1_Monkeypox_virus_isolate_MPXV-M2957_Lagos
MN346693.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Ponan	MT903339.1_Monkeypox_virus_isolate_MPXV-M3021_Delta
MN346694.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Saro	MT903340.1_Monkeypox_virus_isolate_MPXV-M5312_HM12_Rivers
MN346695.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Sidonie	MT903341.1_Monkeypox_virus_isolate_MPXV-M5320_M15_Bayelsa
MN346696.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_North_Surprise_1	MT903342.1_Monkeypox_virus_isolate_MPXV-Singapore
MN346698.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_South_Pushkin	MT903343.1_Monkeypox_virus_isolate_MPXV-UK_P1
MN346699.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_South_Ravel_1	MT903344.1_Monkeypox_virus_isolate_MPXV-UK_P2
MN346700.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2017_South_Ravel_2	MT903345.1_Monkeypox_virus_isolate_MPXV-UK_P3
MN346702.1_UNVERIFIED:_Monkeypox_virus_isolate_MP_XV_TNP_2018_East_Paddy	MT903346.1_Monkeypox_virus_isolate_MPXV-USA2003_099_Gambian_Rat
NC_003310.1_Monkeypox_virus_Zaire-96-l-16	MT903347.1_Monkeypox_virus_isolate_MPXV-USA2003_099_Dormouse
	MT903348.1_Monkeypox_virus_isolate_MPXV-USA2003_099_Rope_Squirrel

Conclusion:

Both clades of Monkeypox can be detected using the primer and probe design as shown in the table above.

8.6. Cross contamination

To determine cross-contamination potential on the Kingfisher instrument, a minimum of 20 contrived positive specimens at 5x LoD were run in a checkerboard pattern (Contrived positive specimens containing MPXV plated in every other well)

Acceptance criteria for cross-contamination:

1. ≥90% of contrived positive specimens are positive for MPXV and RNaseP as expected.
2. ≥90% of negative samples are negative for MPXV.
 - a. Note: If less than 90% of negative specimens yield negative detection, the Kingfisher instrument protocol will be re-evaluated.

Results

Well	Well Position	Sample	Target	Reporter	Amp Status	Cq
------	---------------	--------	--------	----------	------------	----

				Page 15 7.24.22		
				Analysis of Monkeypox Virus with RT-qPCR Validation Data		

MonkeyPox Assay Report

2	A2	NEC-1	MPXV	FAM	No Amp	Undetermined
2	A2	NEC-1	RNAse P	VIC	Inconclusive	39.03
3	A3	MPX-5	MPXV	FAM	Amp	34.33
3	A3	MPX-5	RNAse P	VIC	Amp	16.05
4	A4	NEC-9	MPXV	FAM	No Amp	Undetermined
4	A4	NEC-9	RNAse P	VIC	Amp	37.27
6	A6	NEC-13	MPXV	FAM	No Amp	Undetermined
6	A6	NEC-13	RNAse P	VIC	No Amp	Undetermined
8	A8	MPX-17	MPXV	FAM	Amp	33.80
8	A8	MPX-17	RNAse P	VIC	Amp	15.92
10	A10	NEC-21	MPXV	FAM	No Amp	Undetermined
10	A10	NEC-21	RNAse P	VIC	No Amp	Undetermined
26	B2	MPX-1	MPXV	FAM	Amp	33.54
26	B2	MPX-1	RNAse P	VIC	Amp	15.91
27	B3	NEC-5	MPXV	FAM	No Amp	Undetermined
27	B3	NEC-5	RNAse P	VIC	No Amp	Undetermined
28	B4	MPX-9	MPXV	FAM	Amp	33.00
28	B4	MPX-9	RNAse P	VIC	Amp	15.92
30	B6	MPX-13	MPXV	FAM	Amp	34.92
30	B6	MPX-13	RNAse P	VIC	Amp	15.99
32	B8	NEC-17	MPXV	FAM	No Amp	Undetermined
32	B8	NEC-17	RNAse P	VIC	Inconclusive	37.50
34	B10	MPX-21	MPXV	FAM	Amp	34.35
34	B10	MPX-21	RNAse P	VIC	Amp	15.79
36	B12	NEC1	MPXV	FAM	Inconclusive	39.47
36	B12	NEC1	RNAse P	VIC	No Amp	Undetermined
50	C2	NEC-2	MPXV	FAM	Inconclusive	38.64
50	C2	NEC-2	RNAse P	VIC	No Amp	Undetermined
51	C3	MPX-6	MPXV	FAM	Amp	33.55
51	C3	MPX-6	RNAse P	VIC	Amp	15.83
52	C4	NEC-10	MPXV	FAM	No Amp	Undetermined
52	C4	NEC-10	RNAse P	VIC	No Amp	Undetermined
54	C6	NEC-14	MPXV	FAM	No Amp	Undetermined
54	C6	NEC-14	RNAse P	VIC	No Amp	Undetermined
56	C8	MPX-18	MPXV	FAM	Amp	33.83
56	C8	MPX-18	RNAse P	VIC	Amp	15.85
58	C10	NEC-22	MPXV	FAM	No Amp	Undetermined
58	C10	NEC-22	RNAse P	VIC	No Amp	Undetermined
60	C12	NEC2	MPXV	FAM	No Amp	Undetermined
60	C12	NEC2	RNAse P	VIC	No Amp	Undetermined
74	D2	MPX-2	MPXV	FAM	Amp	34.03
74	D2	MPX-2	RNAse P	VIC	Amp	16.07
75	D3	NEC-6	MPXV	FAM	No Amp	Undetermined
75	D3	NEC-6	RNAse P	VIC	Amp	36.73
76	D4	MPX-10	MPXV	FAM	Amp	34.11
76	D4	MPX-10	RNAse P	VIC	Amp	15.92
78	D6	MPX-14	MPXV	FAM	Amp	34.31
78	D6	MPX-14	RNAse P	VIC	Amp	15.87
80	D8	NEC-18	MPXV	FAM	No Amp	Undetermined
80	D8	NEC-18	RNAse P	VIC	No Amp	Undetermined
82	D10	MPX-22	MPXV	FAM	Amp	34.22
82	D10	MPX-22	RNAse P	VIC	Amp	15.69
98	E2	NEC-3	MPXV	FAM	No Amp	Undetermined
98	E2	NEC-3	RNAse P	VIC	Amp	37.07

MonkeyPox Assay Report

99	E3	MPX-7	MPXV	FAM	Amp	34.75
99	E3	MPX-7	RNAse P	VIC	Amp	15.98
100	E4	NEC-11	MPXV	FAM	No Amp	Undetermined
100	E4	NEC-11	RNAse P	VIC	Amp	36.97
102	E6	NEC-15	MPXV	FAM	No Amp	Undetermined
102	E6	NEC-15	RNAse P	VIC	No Amp	Undetermined
104	E8	MPX--19	MPXV	FAM	Amp	34.25
104	E8	MPX--19	RNAse P	VIC	Amp	15.81
106	E10	NEC-23	MPXV	FAM	No Amp	Undetermined
106	E10	NEC-23	RNAse P	VIC	Inconclusive	38.92
122	F2	MPX-3	MPXV	FAM	Amp	33.94
122	F2	MPX-3	RNAse P	VIC	Amp	15.92
123	F3	NEC-7	MPXV	FAM	No Amp	Undetermined
123	F3	NEC-7	RNAse P	VIC	No Amp	Undetermined
124	F4	MPX-11	MPXV	FAM	Amp	33.48
124	F4	MPX-11	RNAse P	VIC	Amp	15.83
126	F6	MPX-15	MPXV	FAM	Amp	34.86
126	F6	MPX-15	RNAse P	VIC	Amp	15.78
128	F8	NEC-19	MPXV	FAM	No Amp	Undetermined
128	F8	NEC-19	RNAse P	VIC	Inconclusive	37.83
130	F10	MPX-23	MPXV	FAM	Amp	34.10
130	F10	MPX-23	RNAse P	VIC	Amp	15.86
146	G2	NEC-4	MPXV	FAM	No Amp	Undetermined
146	G2	NEC-4	RNAse P	VIC	Inconclusive	38.45
147	G3	MPX-8	MPXV	FAM	Amp	34.42
147	G3	MPX-8	RNAse P	VIC	Amp	15.85
148	G4	NEC-12	MPXV	FAM	No Amp	Undetermined
148	G4	NEC-12	RNAse P	VIC	Amp	37.56
150	G6	NEC-16	MPXV	FAM	No Amp	Undetermined
150	G6	NEC-16	RNAse P	VIC	Inconclusive	38.52
152	G8	MPX-20	MPXV	FAM	Amp	34.64
152	G8	MPX-20	RNAse P	VIC	Amp	15.85
154	G10	NEC-24	MPXV	FAM	No Amp	Undetermined
154	G10	NEC-24	RNAse P	VIC	No Amp	Undetermined
170	H2	MPX-4	MPXV	FAM	Amp	34.40
170	H2	MPX-4	RNAse P	VIC	Amp	16.19
171	H3	NEC-8	MPXV	FAM	No Amp	Undetermined
171	H3	NEC-8	RNAse P	VIC	No Amp	Undetermined
172	H4	MPX-12	MPXV	FAM	Amp	33.89
172	H4	MPX-12	RNAse P	VIC	Amp	15.70
174	H6	MPX-16	MPXV	FAM	Amp	35.01
174	H6	MPX-16	RNAse P	VIC	Amp	15.59
176	H8	NEC-20	MPXV	FAM	Inconclusive	19.00
176	H8	NEC-20	RNAse P	VIC	No Amp	Undetermined
178	H10	MPX-24	MPXV	FAM	Amp	35.86
178	H10	MPX-24	RNAse P	VIC	Amp	15.93
180	H12	PC	MPXV	FAM	Amp	25.68
180	H12	PC	RNAse P	VIC	Amp	26.58
384	P24	NTC	MPXV	FAM	No Amp	Undetermined
384	P24	NTC	RNAse P	VIC	No Amp	Undetermined

Conclusion: No cross contamination was observed.

8.7. Cross Reactivity (Analytical Specificity)

Cross-reactivity studies were performed to demonstrate that the test does not react with related pathogens, high prevalence disease agents, and normal or pathogenic flora that are reasonably likely to be encountered in a clinical sample. A wet testing with Similar organism(s) will be performed using higher copies/ml.

Orthopox family virus was used to conduct the studies for the Cross reactivity. Cowpox virus, Camel pox virus and rabbit pox virus were used for the studies.

Results:

Sample	Target	Amp Status	Cq
CowpoxVirus-1	MPXV	Amp	32.02
CowpoxVirus-1	RNase P	Amp	23.55
CowpoxVirus-2	MPXV	Amp	33.12
CowpoxVirus-2	RNase P	Amp	24.08
CowpoxVirus-3	MPXV	Amp	32.54
CowpoxVirus-3	RNase P	Amp	23.65
MPXVirus-1	MPXV	Amp	27.14
MPXVirus-1	RNase P	Amp	26.35
CamelpoxVirus-1	MPXV	Amp	29.90
CamelpoxVirus-1	RNase P	Amp	16.81
CamelpoxVirus-2	MPXV	Amp	30.90
CamelpoxVirus-2	RNase P	Amp	16.75
CamelpoxVirus-3	MPXV	Amp	30.72
CamelpoxVirus-3	RNase P	Amp	16.69
RabbitpoxVirus-1	MPXV	No Amp	Undetermined
RabbitpoxVirus-1	RNase P	Amp	38.03
RabbitpoxVirus-2	MPXV	No Amp	Undetermined
RabbitpoxVirus-2	RNase P	No Amp	Undetermined
RabbitpoxVirus-3	MPXV	No Amp	Undetermined
RabbitpoxVirus-3	RNase P	No Amp	Undetermined
PC	MPXV	Amp	24.47
PC	RNase P	Amp	25.16
NTC-2	MPXV	No Amp	Undetermined
NTC-2	RNase P	Amp	38.01
NTC-1	MPXV	No Amp	Undetermined
NTC-1	RNase P	Inconclusive	37.86

Conclusion:

The assay can detect related orthopoxviruses, including Monkeypox virus. Further testing will be done to confirm other orthopoxviruses. Rabbitpox will be evaluated further.

8.8. Interfering substances

Pooled negative saliva specimens will be spiked with known positive sample at 2x LoD and potential interfering substances at the concentrations below. Each substance will be tested in 10 replicates. Any test substance that fails to meet acceptance criteria may be evaluated at lower concentrations to establish the concentration at which the substance is tolerated.

Interfering Substance	Concentration
Blood (Human) -B	1% v/v
Colgate toothpaste-T	0.25% v/v
Cepacol throat lozenges (menthol + Benzocaine)-C	5 mg/mL
Crest Mouthwash-M	2.5% v/v
Human DNA-DNA	10ng/uL

Acceptance criteria for interfering substances:

1. ≥90% of replicates are positive for MPXV specimens. If less than 90% are in agreement, the substance will be diluted to determine the concentration that is tolerated by the assay.

Results

Sample	Target	Amp Status	Cq
NEC-1	MPXV	No Amp	Undetermined
NEC-1	RNAse P	Amp	36.79
MPXV_B-1	MPXV	Amp	34.02
MPXV_B-1	RNAse P	Amp	16.31
MPXV_B-2	MPXV	Amp	34.96
MPXV_B-2	RNAse P	Amp	15.43
MPXV_B-3	MPXV	Amp	33.64
MPXV_B-3	RNAse P	Amp	15.71
MPXV_B-4	MPXV	Amp	35.92
MPXV_B-4	RNAse P	Amp	15.73
MPXV_B-5	MPXV	Amp	36.75
MPXV_B-5	RNAse P	Amp	15.88
MPXV_B-6	MPXV	Amp	36.03
MPXV_B-6	RNAse P	Amp	15.85
MPXV_B-7	MPXV	Amp	35.45
MPXV_B-7	RNAse P	Amp	15.65
MPXV_B-8	MPXV	Amp	34.12
MPXV_B-8	RNAse P	Amp	16.96
MPXV_B-9	MPXV	No Amp	Undetermined
MPXV_B-9	RNAse P	Amp	15.70
MPXV_B-10	MPXV	Amp	35.96
MPXV_B-10	RNAse P	Amp	16.02
NEC-2	MPXV	No Amp	Undetermined
NEC-2	RNAse P	No Amp	Undetermined

MonkeyPox Assay Report

MPXV-T-1	MPXV	Amp	35.47
MPXV-T-1	RNAse P	Amp	16.85
MPXV-T-2	MPXV	Amp	36.08
MPXV-T-2	RNAse P	Amp	16.48
MPXV-T-3	MPXV	Amp	36.93
MPXV-T-3	RNAse P	Amp	16.77
MPXV-T-4	MPXV	Amp	36.79
MPXV-T-4	RNAse P	Amp	16.95
MPXV-T-5	MPXV	Amp	36.02
MPXV-T-5	RNAse P	Amp	16.13
MPXV-T-6	MPXV	Amp	32.77
MPXV-T-6	RNAse P	Amp	15.91
MPXV-T-7	MPXV	Amp	33.70
MPXV-T-7	RNAse P	Amp	15.57
MPXV-T-8	MPXV	Amp	32.44
MPXV-T-8	RNAse P	Amp	15.26
MPXV-T-9	MPXV	Amp	22.50
MPXV-T-9	RNAse P	Amp	15.23
MPXV-T-10	MPXV	Amp	21.20
MPXV-T-10	RNAse P	Amp	15.01
NEC-3	MPXV	No Amp	Undetermined
NEC-3	RNAse P	Amp	38.11
MPXV-M-1	MPXV	Amp	35.59
MPXV-M-1	RNAse P	Amp	16.35
MPXV-M-2	MPXV	Amp	32.90
MPXV-M-2	RNAse P	Amp	16.22
MPXV-M-3	MPXV	Amp	35.72
MPXV-M-3	RNAse P	Amp	16.21
MPXV-M-4	MPXV	Amp	34.62
MPXV-M-4	RNAse P	Amp	16.16
MPXV-M-5	MPXV	Amp	34.15
MPXV-M-5	RNAse P	Amp	16.15
MPXV-M-6	MPXV	Amp	34.11
MPXV-M-6	RNAse P	Amp	16.04
MPXV-M-7	MPXV	Amp	33.54
MPXV-M-7	RNAse P	Amp	16.14
MPXV-M-8	MPXV	Amp	33.87
MPXV-M-8	RNAse P	Amp	16.17
MPXV-M-9	MPXV	Amp	34.58
MPXV-M-9	RNAse P	Amp	16.10
MPXV-M-10	MPXV	Amp	33.86
MPXV-M-10	RNAse P	Amp	16.07
MPXV_C-1	MPXV	Amp	35.65
MPXV_C-1	RNAse P	Amp	15.87
MPXV_C-2	MPXV	Amp	37.13
MPXV_C-2	RNAse P	Amp	16.18
MPXV_C-3	MPXV	Amp	34.32
MPXV_C-3	RNAse P	Amp	15.74
MPXV_C-4	MPXV	Amp	35.60
MPXV_C-4	RNAse P	Amp	15.66
MPXV_C-5	MPXV	Amp	35.97
MPXV_C-5	RNAse P	Amp	15.83
MPXV_C-6	MPXV	Amp	36.60
MPXV_C-6	RNAse P	Amp	15.90

MonkeyPox Assay Report

MPXV_C-7	MPXV	Amp	34.51
MPXV_C-7	RNAse P	Amp	16.03
MPXV_C-8	MPXV	Amp	36.71
MPXV_C-8	RNAse P	Amp	16.20
MPXV_C-9	MPXV	Amp	31.81
MPXV_C-9	RNAse P	Amp	14.20
MPXV_C-10	MPXV	No Amp	Undetermined
MPXV_C-10	RNAse P	Amp	16.28
MPXV_DNA-1	MPXV	Amp	35.64
MPXV_DNA-1	RNAse P	Amp	16.43
MPXV_DNA-2	MPXV	Amp	35.18
MPXV_DNA-2	RNAse P	Amp	16.26
MPXV_DNA-3	MPXV	Amp	34.79
MPXV_DNA-3	RNAse P	Amp	16.25
MPXV_DNA-4	MPXV	Amp	35.02
MPXV_DNA-4	RNAse P	Amp	16.17
MPXV_DNA-5	MPXV	Amp	34.61
MPXV_DNA-5	RNAse P	Amp	16.13
MPXV_DNA-6	MPXV	Amp	37.58
MPXV_DNA-6	RNAse P	Amp	16.30
MPXV_DNA-7	MPXV	Amp	35.62
MPXV_DNA-7	RNAse P	Amp	16.09
MPXV_DNA-8	MPXV	Amp	35.19
MPXV_DNA-8	RNAse P	Amp	16.18
MPXV_DNA-9	MPXV	Amp	35.51
MPXV_DNA-9	RNAse P	Amp	16.12
MPXV_DNA-10	MPXV	No Amp	Undetermined
MPXV_DNA-10	RNAse P	Amp	16.79
NTC	MPXV	No Amp	Undetermined
NTC	RNAse P	No Amp	Undetermined
PC-1	MPXV	Amp	18.88
PC-1	RNAse P	Amp	19.93

Conclusion:

Each substance was tested at the given standard concentrations. No interference effects were observed for any of the substances at the concentrations tested except for blood and human DNA. One sample spiked with blood and another with human DNA did not show amplification. However, the study was still within the 95% acceptable range so no further testing was required.

8.9. Stability

The known positive samples were prepared at two different dilutions and stored at room temperature and 4 degree celcius over the course of 8 days (0, 1, 4, 8 days). Data for day 0 and day 1 is shown below. The report will be updated when data for the remainder of the days is available.

		RT				RT	
		DAY 0				DAY 1	
Sample	Target	Amp Status	Cq		Sample	Amp Status	Cq
NEC-33	MPXV	No Amp	Undetermined		NEC1	No Amp	Undetermined
NEC-33	RNAse P	Inconclusive	38.53		NEC1	No Amp	Undetermined
NEC-34	MPXV	No Amp	Undetermined		NEC2	No Amp	Undetermined
NEC-34	RNAse P	No Amp	Undetermined		NEC2	Inconclusive	37.52

MonkeyPox Assay Report

NEC-35	MPXV	No Amp	Undetermined		NEC3	Inconclusive	39.84
NEC-35	RNAse P	Inconclusive	38.25		NEC3	Inconclusive	38.41
Patient2-1x-0-1	MPXV	Amp	23.56		Patient2-1x-RT-1	Amp	23.66
Patient2-1x-0-1	RNAse P	Amp	15.13		Patient2-1x-RT-1	Amp	16.42
Patient2-1x-0-2	MPXV	Amp	23.53		Patient2-1x-RT-2	Amp	23.93
Patient2-1x-0-2	RNAse P	Amp	15.17		Patient2-1x-RT-2	Amp	16.33
Patient2-1x-0-3	MPXV	Amp	23.45		Patient2-1x-RT-3	Amp	24.20
Patient2-1x-0-3	RNAse P	Amp	15.17		Patient2-1x-RT-3	Amp	16.34
Patient2-2x-0-1	MPXV	Amp	24.71		Patient2-2x-RT-1	Amp	25.09
Patient2-2x-0-1	RNAse P	Amp	15.00		Patient2-2x-RT-1	Amp	16.00
Patient2-2x-0-2	MPXV	Amp	24.33		Patient2-2x-RT-2	Amp	24.90
Patient2-2x-0-2	RNAse P	Amp	14.86		Patient2-2x-RT-2	Amp	15.76
Patient2-2x-0-3	MPXV	Amp	24.53		Patient2-2x-RT-3	Amp	25.09
Patient2-2x-0-3	RNAse P	Amp	15.05		Patient2-2x-RT-3	Amp	16.02
Negative Saliva-0-1	MPXV	No Amp	Undetermined		NegSaliva-1-1	No Amp	Undetermined
Negative Saliva-0-1	RNAse P	Amp	14.92		NegSaliva-1-1	Amp	16.33
Negative Saliva-0-2	MPXV	No Amp	Undetermined		NegSaliva-1-2	No Amp	Undetermined
Negative Saliva-0-2	RNAse P	Amp	14.99		NegSaliva-1-2	Amp	16.23
Negative Saliva-0-3	MPXV	No Amp	Undetermined		NegSaliva-1-3	No Amp	Undetermined
Negative Saliva-0-3	RNAse P	Amp	14.80		NegSaliva-1-3	Amp	16.22
Negative Saliva -0-4	MPXV	Inconclusive	24.95		NegSaliva-1--4	No Amp	Undetermined
Negative Saliva -0-4	RNAse P	Amp	14.84		NegSaliva-1--4	Amp	15.94
		4 °C				4 °C	
		DAY 0				DAY 1	
Sample	Target	Amp Status	Cq		Sample	Amp Status	Cq
NEC-36	MPXV	Inconclusive	21.37		NEC4	No Amp	Undetermined
NEC-36	RNAse P	Inconclusive	15.48		NEC4	No Amp	Undetermined
NEC-37	MPXV	No Amp	Undetermined		NEC5	No Amp	Undetermined
NEC-37	RNAse P	No Amp	Undetermined		NEC5	No Amp	Undetermined
NEC-38	MPXV	Inconclusive	37.05		NEC6	No Amp	Undetermined
NEC-38	RNAse P	Inconclusive	27.88		NEC6	Amp	36.77
Patient2-1x-0-1-4C	MPXV	Amp	23.65		Patient2-1x-4C-1	Amp	23.90
Patient2-1x-0-1-4C	RNAse P	Amp	15.52		Patient2-1x-4C-1	Amp	16.06
Patient2-1x-0-2-4C	MPXV	Amp	22.81		Patient2-1x-4C-2	Amp	23.79
Patient2-1x-0-2-4C	RNAse P	Amp	15.17		Patient2-1x-4C-2	Amp	15.98
Patient2-1x-0-3-4C	MPXV	Amp	23.88		Patient2-1x-4C-3	Amp	23.94
Patient2-1x-0-3-4C	RNAse P	Amp	15.25		Patient2-1x-4C-3	Amp	16.16
Pateint2-2x-0-1-4C	MPXV	Amp	24.61		Patient2-2x-4C-1	Amp	24.88
Pateint2-2x-0-1-4C	RNAse P	Amp	15.10		Patient2-2x-4C-1	Amp	15.96
Pateint2-2x-0-2-4C	MPXV	Amp	24.74		Patient2-2x-4C-2	Amp	24.76
Pateint2-2x-0-2-4C	RNAse P	Amp	15.00		Patient2-2x-4C-2	Amp	15.94
Pateint2-2x-0-3-4C	MPXV	Amp	24.28		Patient2-2x-4C-3	Amp	24.53
Pateint2-2x-0-3-4C	RNAse P	Amp	14.89		Patient2-2x-4C-3	Amp	16.06
Negative Saliva-1-0	MPXV	No Amp	Undetermined		NegSaliva-1-01	No Amp	Undetermined
Negative Saliva-1-0	RNAse P	Amp	13.98		NegSaliva-1-01	Amp	14.68
Negative Saliva-2-0	MPXV	No Amp	Undetermined		NegSaliva-01-2	No Amp	Undetermined
Negative Saliva-2-0	RNAse P	Amp	14.14		NegSaliva-01-2	Amp	14.98
Negative Saliva-3-0	MPXV	No Amp	Undetermined		NegSaliva-01-3	No Amp	Undetermined
Negative Saliva-3-0	RNAse P	Amp	14.06		NegSaliva-01-3	Amp	14.99
Negative Saliva-4-0	MPXV	No Amp	Undetermined		NegSaliva-01-4	No Amp	Undetermined
Negative Saliva-4-0	RNAse P	Amp	14.11		NegSaliva-01-4	Amp	14.98
PC-1	MPXV	Amp	18.88		PC-1	Amp	25.58
PC-1	RNAse P	Amp	19.93		PC-1	Amp	26.60
NTC1	MPXV	No Amp	Undetermined		NTC2	No Amp	Undetermined
NTC1	RNAse P	Inconclusive	37.85		NTC2	Inconclusive	38.09

Conclusion:

No significance difference was observed on day0 and day1-Sample was stable.